Fischer Medical Ventures’ associate company, Nanyang Biologics (NYB), has entered into a strategic collaboration with global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build VECURA – an AI-powered drug discovery platform that combines advanced predictive models with a proprietary library of millions of natural compounds.  

Through this initiative, Nanyang Biologics aims to accelerate the development of next-generation health solutions across pharmaceuticals, dietary supplements, functional foods, and personal care.

Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the therapeutic drug discovery timeline from the traditional 10–12 years to just a few hours. It is expected to become the world’s largest AI-curated compound library.

To formalise this alliance, a Memorandum of Understanding (MoU) was signed between NYB, NVIDIA, HPE, and Equinix during the inaugural AI4Life Summit 2025 at The Fullerton Hotel, Singapore.

Dr. Roland Ong, Chairman of Nanyang Biologics, said, “By partnering with global technology leaders, we are creating a collaborative ecosystem that will accelerate drug discovery and unlock new therapeutic possibilities for patients worldwide.”

As India’s first company to indigenously manufacture high-quality MRI systems and a leader in breakthrough diagnostic solutions, Fischer Medical Ventures (FMV) is now expanding into the preventative healthcare space through its partnership with Nanyang Biologics.

Ravindran Govindan, Executive Chairman and MD of FMV, said, “We believe that with the strong support of world-class companies like NVIDIA, HPE and Equinix, NYB’s supercharged VECURA platform will unleash powerful therapeutic potential of nature with AI and discover millions of valuable natural compounds in shorter time to enable any Biotech companies to use to develop their health and wellness products faster.”

Headquartered in Singapore, Nanyang Biologics applies AI and biological data to map drug–target interactions in disease pathways. By leveraging advanced machine learning, the company accelerates the discovery of next-generation treatments for cancer, chronic diseases, and wellness applications.